查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924690

大容量注射劑市場按產品類型、包裝、最終用戶、應用和分銷管道分類－2026-2032年全球預測

Large Volume Parenteral Market by Product Type, Packaging, End User, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，大容量注射劑市場價值將達到 37.4 億美元，到 2026 年將成長至 39.9 億美元，年複合成長率為 7.74%，到 2032 年將達到 63 億美元。

關鍵市場統計數據
基準年 2025 37.4億美元
預計年份：2026年 39.9億美元
預測年份 2032 63億美元
複合年成長率 (%) 7.74%

大劑量注射療法的策略實施：臨床影響、供應鏈複雜性以及塑造醫療服務提供的技術和監管演變框架

大容量腸外營養療法仍是急性慢性治療路徑中的重要組成部分，為維持體液平衡、血流動力學穩定、藥物輸注和營養支持提供關鍵支持。臨床需求廣泛，涵蓋圍手術全期管理和重症監護復甦，以及門診靜脈輸液和長期經腸營養。在此背景下，臨床最佳實踐、不斷變化的醫療環境和不斷發展的生產標準相互作用，造就了複雜的產業格局。

識別將改變臨床實踐、生產模式和供應鏈韌性的關鍵轉折點，從而在全球範圍內重新定義大容量注射劑領域。

大容量注射劑領域正經歷著變革性的轉變，影響著臨床實務、生產結構和商業模式。在臨床方面，護理路徑正顯著地向以患者為中心的模式轉變，優先考慮門診給藥、短期住院和家庭輸注方案。這種轉變迫使生產者和醫療服務提供者調整配方、包裝和使用說明，以支持在傳統急診環境之外的安全給藥。

評估2025年美國關稅調整對採購、生產獎勵、成本結構和策略供應鏈重組的累積影響

近期主要經濟體採取的關稅措施對大劑量注射劑產業的籌資策略、供應商選擇和生產經濟效益產生了連鎖反應。關稅相關的成本壓力促使相關人員重新評估其全球採購基礎，提高關鍵部件的本地化程度，並重新談判供應商契約，以降低原料價格波動帶來的風險。為此，許多企業正在調整庫存緩衝，並採取近岸外包策略，以減少跨國政策波動帶來的風險。

提供可操作的細分洞察，揭示產品類型、最終用戶、包裝形式、應用和分銷管道如何相互作用，從而推動臨床和商業性優先事項的發展。

細緻的市場區隔觀點揭示了產品屬性、臨床環境、包裝、臨床應用和通路如何共同影響採購和臨床決策。從產品類型來看，市場可分為膠體和晶體。膠體包括白蛋白、聚葡萄糖、明膠和羥乙基澱粉，而晶體包括平衡電解質溶液、葡萄糖、生理食鹽水水和乳酸林格氏液。每種製劑類別都有其獨特的治療特性和監管要求，這些都會影響臨床選擇、標籤要求和保存期限管理。

影響採購、製造地和監管應對措施的區域趨勢和戰略重點（美洲、歐洲、中東、非洲、亞太地區）

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的製造策略、監管互動和採購行為有著深遠的影響，因為這些地區的商業環境各不相同。在美洲，一體化的醫療保健系統和中央採購組織推動了規模效益的提升，而強大的本土製造能力則幫助企業快速應對需求激增。同時，在歐洲、中東和非洲地區，不同的管理體制和採購模式意味著監管協調、本地臨床證據以及與經銷商的關係是實現廣泛市場進入的關鍵。

企業策略情報揭示了領先的大容量注射劑領域關鍵相關人員的競爭定位、製造能力、夥伴關係模式和創新方法

大容量注射劑領域的競爭動態取決於卓越的生產製造能力、合規性、夥伴關係模式和創新速度。主要企業通常將強大的無菌生產能力與檢驗的包裝系統結合，以滿足多樣化的臨床需求和監管要求。契約製造和填充包裝公司在擴大產能、幫助新參與企業達到品質標準以及避免重複資本投資方面發揮關鍵作用。

為行業領導者提供切實可行的建議，以增強注射劑護理領域的供應鏈韌性、最佳化產品系列併加速以患者為中心的交付路徑。

業界領導者應採取一系列切實可行的舉措，以增強韌性、保障利潤並改善患者療效。首先，應擴大區域製造和雙源採購策略，以降低貿易政策變化和物流中斷帶來的風險。建立檢驗的替代供應商以及區域填充和包裝能力，既能確保生產的連續性，又能靈活調配產能以滿足突發的臨床需求。

透明的調查方法，明確列出了資料來源、專家諮詢、檢驗通訊協定和分析框架，以支持報告基於證據的結論。

本報告的研究結合了結構化的原始研究和嚴謹的二手研究，並輔以分析三角驗證和品質保證通訊協定。原始研究包括對臨床醫生、採購主管、生產經理和供應鏈專家進行深入訪談，以了解實際營運和未來發展重點。這些專家的見解與二級資訊來源（包括監管指南、技術標準和已發表的臨床文獻）相結合，以確保證據基礎的全面性。

簡潔的結論整合了對臨床醫生、製造商、支付方和採購團隊的實際意義，以應對大容量注射劑不斷變化的現實。

總之，大容量注射治療的關鍵在於臨床需求與運作複雜性的交會點。不斷變化的醫療環境、供應鏈的脆弱性、包裝創新以及日益嚴格的監管審查，共同構成了挑戰，同時也帶來了競爭優勢。透過將臨床優先事項與生產的柔軟性和分銷能力相結合，相關人員可以在降低風險的同時，提升患者照護水準。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的大容量注射市場

  • 膠體製劑
    • 白蛋白
    • 聚葡萄糖
    • 明膠
    • 羥乙基澱粉
  • 晶體溶液
    • 平衡電解質溶液
    • 葡萄糖
    • 生理食鹽水
    • 林格氏乳酸鹽溶液

9. 依包裝類型分類的大容量注射市場

  • 包包
  • 瓶子
    • 塑膠
    • 玻璃

第10章 以最終用戶分類的大容量注射劑市場

  • 門診治療
  • 診所
  • 居家醫療
  • 醫院

第11章 依應用分類的大容量注射市場

  • 血容量擴張
  • 靜脈輸液補充
  • 藥物輸送
  • 營養支持

第12章 按分銷管道分類的大容量注射劑市場

  • 離線
  • 線上

第13章：各區域大容量注射市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 大容量注射劑市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國大容量注射劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國大容量注射劑市場

第17章 中國大容量注射劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories Inc.
  • Albert David Ltd.
  • Amanta Healthcare
  • B. Braun Melsungen AG
  • BAG Healthcare GmbH
  • Baxter International Inc.
  • Becton Dickinson & Co.（BD）
  • Beximco Pharmaceutical Ltd.
  • Cipla Limited
  • Cook Pharmica LLC
  • Fresenius Kabi AG
  • Grifols SA
  • ICU Medical Inc.
  • JW Life Science
  • Otsuka Pharmaceutical Co.（Otsuka Holdings Co., Ltd.）
  • Pfizer Inc.（including Hospira assets）
  • Sandoz（a spin-off of Novartis）
  • Sichuan Kelun Pharmaceutical Co., Ltd.
  • Terumo Corp.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-7A380DA7C42A

The Large Volume Parenteral Market was valued at USD 3.74 billion in 2025 and is projected to grow to USD 3.99 billion in 2026, with a CAGR of 7.74%, reaching USD 6.30 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.74 billion
Estimated Year [2026] USD 3.99 billion
Forecast Year [2032] USD 6.30 billion
CAGR (%) 7.74%

A strategic introduction to large volume parenteral therapy that frames clinical significance, supply chain intricacies, and technological regulatory evolutions shaping care delivery

Large volume parenteral therapies remain foundational to acute and chronic care pathways, providing indispensable support for fluid balance, hemodynamic stabilization, medication delivery, and nutritional supplementation. The clinical imperative is broad, spanning perioperative management, critical care resuscitation, ambulatory intravenous therapies, and long-term parenteral nutrition. Against this backdrop, the industry's operational landscape has grown more complex, driven by the interplay of clinical best practices, changing care settings, and evolving manufacturing norms.

Supply chains for large volume parenterals are characterized by precision, regulatory oversight, and a reliance on both specialized raw materials and validated aseptic manufacturing environments. At the same time, advancements in formulation, container closure systems, and delivery devices continue to influence prescribing behavior and procurement decisions. Regulatory agencies are increasingly focused on sterility assurance, stability data, and labeling that supports safe use across diverse care settings, which in turn elevates pre-market scrutiny and post-market vigilance.

Given these dynamics, stakeholders must navigate a landscape where clinical needs, product design, and regulatory expectations converge. This introduction establishes the strategic parameters that frame subsequent sections, emphasizing the need for integrated clinical, manufacturing, and commercial approaches to manage risk and seize opportunities in the large volume parenteral arena.

Identification of transformative shifts altering clinical practice, manufacturing paradigms, and supply resilience that are redefining large volume parenteral landscapes globally

The large volume parenteral arena is undergoing transformative shifts that touch clinical practice, manufacturing architecture, and commercial models. Clinically, there is an observable movement toward patient-centric care pathways that prioritize outpatient administration, shorter hospital stays, and home-based infusion solutions. This shift compels manufacturers and providers to adapt formulations, packaging formats, and instructions for use to support safe administration outside traditional acute-care settings.

Manufacturing and sourcing are also changing. Firms are investing in modular aseptic production, single-use technologies, and expanded regional manufacturing footprints to increase flexibility and reduce exposure to supply disruptions. Concurrently, sustainability considerations and circular-economy initiatives are influencing packaging choices and waste-management strategies, prompting development of lighter-weight containers and recyclable materials.

From a commercial perspective, digital tools for demand forecasting, traceability, and post-market surveillance are gaining traction. Real-time inventory visibility and quality-attribute tracking foster tighter collaboration among producers, distributors, and large health systems. Regulatory expectations are evolving in parallel, with authorities emphasizing robustness of sterility controls and transparency of raw material provenance. Collectively, these transformative shifts are redefining competitive advantage, favoring organizations that can integrate clinical insight, manufacturing agility, and data-driven supply chain resilience.

Assessment of the cumulative impact of United States tariff adjustments in 2025 on sourcing, production incentives, cost structures, and strategic supply chain reconfiguration

Recent tariff measures implemented by a major economy have produced ripple effects across procurement strategies, supplier selection, and manufacturing economics within the large volume parenteral sector. Tariff-related cost pressures have encouraged stakeholders to reassess global sourcing footprints, accelerate localization initiatives for critical components, and renegotiate supplier contracts to mitigate input-price volatility. In response, many organizations are recalibrating inventory buffers and adopting nearshoring strategies to reduce exposure to cross-border policy shifts.

These trade-policy developments have also catalyzed a reexamination of supplier relationships, prompting deeper collaboration on total landed cost modeling, quality alignment, and contractual flexibility. Manufacturers with diversified supplier bases and regional manufacturing capabilities have greater latitude to stabilize supply and protect margins. Likewise, procurement teams are increasingly leveraging long-term strategic partnerships and multi-sourcing models to maintain continuity of supply while managing incremental cost burdens.

Policy-driven cost impacts extend to downstream stakeholders as well, influencing hospital procurement cycles, pharmacy stocking strategies, and distributor pricing mechanics. As a consequence, health systems are exploring alternative clinical protocols and formulation choices where therapeutically appropriate, and manufacturers are accelerating product rationalization and packaging optimization efforts. Looking forward, trade policy will remain a decisive variable informing investment in production capacity, risk mitigation frameworks, and cross-border logistics optimization.

Actionable segmentation insights revealing how product types, end users, packaging formats, applications, and distribution channels interact to drive clinical and commercial priorities

A nuanced segmentation perspective illuminates how product attributes, care settings, packaging formats, clinical applications, and distribution pathways collectively shape procurement and clinical decisions. From the product type viewpoint, the landscape divides into colloids and crystalloids, with colloids encompassing albumin, dextrans, gelatins, and hydroxyethyl starch, and crystalloids covering balanced electrolyte solutions, dextrose, normal saline, and Ringer's lactate. Each formulation class carries distinct therapeutic profiles and regulatory considerations that influence clinical selection, labeling requirements, and shelf-life management.

End-user segmentation further refines demand patterns across ambulatory care, clinics, home care, and hospitals. Hospitals remain centers for acute resuscitation and complex parenteral nutrition, while ambulatory and home care settings are driving demand for formulations and packaging that support safe administration outside institutional walls. Packaging choices-bags, glass bottles, and plastic bottles, with bags subdivided into flexible plastic pouches and plastic bags-play a pivotal role in logistics, administration technique, and waste handling. Flexible pouches, for example, enable lighter transport weight and reduced cold-chain volume, whereas glass bottles can be preferred for certain stability requirements.

Application-driven segmentation differentiates needs for blood volume expansion, fluid replacement, medication delivery, and nutritional support, the latter of which spans partial parenteral nutrition and total parenteral nutrition. Distribution channels including hospital pharmacies, online pharmacies, and retail pharmacies determine accessibility, ordering cadence, and fulfillment complexity. Integrating these segmentation lenses reveals actionable implications for product design, clinical guidance, and distribution strategies, and underscores the need for tailored commercialization plans aligned with specific end-user workflows and regulatory constraints.

Regional dynamics and strategic priorities across Americas, Europe, Middle East & Africa, and Asia-Pacific that shape procurement, manufacturing footprints, and regulatory interactions

Regional dynamics exert profound influence on manufacturing strategy, regulatory engagement, and procurement behavior across the continentally distinct operating environments of Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated healthcare systems and centralized purchasing entities often drive scale efficiencies, while strong domestic manufacturing capacity supports rapid response to demand surges. Conversely, Europe, Middle East & Africa features a mosaic of regulatory regimes and procurement models, which increases the importance of regulatory harmonization, localized clinical evidence, and distributor relationships to achieve broad market access.

The Asia-Pacific region combines a mix of large domestic manufacturers, rapidly evolving regulatory frameworks, and growing investment in local production capabilities. This environment encourages collaboration between multinational players and regional partners to tailor formulations and packaging that meet local clinical practices and supply chain realities. Across all regions, variations in reimbursement mechanisms, hospital procurement cycles, and logistics infrastructure shape how products are introduced, stocked, and administered.

Given these regional distinctions, successful strategies involve aligning manufacturing footprints with regional demand profiles, engaging early with regulators to address stability and sterility expectations, and designing distribution models that reflect local procurement behaviors. Cross-region comparisons reveal opportunities to leverage best practices in quality assurance, clinical education, and supply chain digitization to build resilient, regionally attuned operations.

Corporate strategic intelligence highlighting competitive positioning, manufacturing capabilities, partnership models, and innovation approaches among leading large volume parenteral stakeholders

Competitive dynamics in the large volume parenteral space are driven by a combination of manufacturing excellence, regulatory compliance, partnership models, and innovation velocity. Leading players typically combine robust aseptic manufacturing capabilities with validated packaging systems, enabling them to meet diverse clinical needs and regulatory expectations. Contract manufacturing and fill-finish specialists play a central role in scaling capacity and enabling market entrants to meet quality thresholds without duplicative capital investment.

Strategic collaborations between formulation specialists, packagers, and distribution partners accelerate time-to-clinic for complex nutritional and medication-delivery products. Companies that invest in end-to-end traceability, serialization, and cold-chain monitoring gain a competitive edge in supply assurance and customer service. At the same time, organizations that integrate clinical affairs and real-world evidence generation into commercial plans are better positioned to influence institutional formularies and protocol adoption.

Operational excellence is complemented by targeted innovation, such as optimization of container closure systems for reduced extractables and leachables, advancement of preservative-free formulations, and development of dosing-friendly formats for ambulatory administration. Collectively, these capabilities define competitive positioning and determine which firms can most effectively respond to evolving clinician preferences, regulatory expectations, and procurement priorities.

Actionable recommendations for industry leaders to strengthen supply resilience, optimize product portfolios, and accelerate patient-centric delivery pathways in parenteral care

Industry leaders should pursue a set of pragmatic actions to strengthen resilience, protect margins, and enhance patient outcomes. First, expand regional manufacturing and dual-sourcing strategies to reduce exposure to trade-policy shifts and logistics disruptions. Establishing validated alternative suppliers and regional fill-finish capacity supports continuity while allowing for responsive allocation of production to meet emergent clinical demand.

Second, prioritize packaging optimization that balances clinical usability, supply chain efficiency, and environmental stewardship. Transitioning to lightweight, recyclable formats and flexible pouch systems where clinically appropriate reduces transportation costs and waste volumes, while maintaining compatibility with bedside administration workflows.

Third, align product portfolios with evolving care settings by developing formulations and administration-ready presentations that facilitate safe use in ambulatory and home care environments. Coupling product design with clinician education and digital adherence tools increases acceptance and supports protocol shifts.

Finally, invest in advanced supply chain visibility and predictive analytics to enable real-time decision-making, proactive risk mitigation, and improved inventory management. These investments should be complemented by stronger partnerships between manufacturers, distributors, and large health systems to create shared accountability for supply continuity and quality outcomes.

Transparent research methodology describing data sources, expert engagement, validation protocols, and analytic frameworks underpinning the report's evidence-based conclusions

The research underpinning this report combines a structured blend of primary engagement and rigorous secondary investigation, complemented by analytic triangulation and quality assurance protocols. Primary inputs included in-depth interviews with clinicians, procurement leaders, manufacturing heads, and supply chain specialists to capture operational realities and forward-looking priorities. These expert perspectives were synthesized with secondary sources such as regulatory guidance, technical standards, and published clinical literature to ensure a comprehensive evidentiary base.

Analytical methods included thematic coding of qualitative interviews, supply chain risk mapping, and comparative assessment of manufacturing and packaging technologies. Findings were validated through iterative expert review sessions to reconcile divergent viewpoints and confirm practical relevance. Data integrity procedures encompassed source verification, cross-referencing of regulatory documents, and internal consistency checks across product, application, and distribution analyses.

Together, these methodological steps ensured that conclusions are grounded in practitioner experience, supported by documented standards, and stress-tested against alternative scenarios. Transparency in these methods enables stakeholders to assess the reliability of insights and to adapt analytic approaches for their own internal planning and validation exercises.

Concise conclusion synthesizing practical implications for clinicians, manufacturers, payers, and procurement teams to navigate evolving large volume parenteral realities

In summary, large volume parenteral care occupies a critical intersection of clinical necessity and operational complexity. The confluence of changing care settings, supply chain sensitivities, packaging innovation, and regulatory scrutiny creates both challenges and avenues for competitive differentiation. By integrating clinical priorities with manufacturing flexibility and distribution intelligence, stakeholders can reduce risk while enhancing patient care delivery.

Strategic emphasis on regional manufacturing alignment, packaging evolution, and multi-channel distribution will be central to building resilient supply networks. Concurrent investment in digital tools for traceability, predictive inventory management, and post-market surveillance will further strengthen system responsiveness. Importantly, clinical and commercial leaders should pursue collaborative models that align incentives across manufacturers, distributors, and health systems to ensure reliable access to high-quality large volume parenteral products.

This conclusion underscores that adaptive, integrated strategies-rooted in operational excellence and clinical alignment-are essential for navigating the evolving landscape and sustaining long-term performance in parenteral therapies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Large Volume Parenteral Market, by Product Type

  • 8.1. Colloids
    • 8.1.1. Albumin
    • 8.1.2. Dextrans
    • 8.1.3. Gelatins
    • 8.1.4. Hydroxyethyl Starch
  • 8.2. Crystalloids
    • 8.2.1. Balanced Electrolyte Solutions
    • 8.2.2. Dextrose
    • 8.2.3. Normal Saline
    • 8.2.4. Ringer's Lactate

9. Large Volume Parenteral Market, by Packaging

  • 9.1. Bags
  • 9.2. Bottles
    • 9.2.1. Plastic
    • 9.2.2. Glass

10. Large Volume Parenteral Market, by End User

  • 10.1. Ambulatory Care
  • 10.2. Clinics
  • 10.3. Home Care
  • 10.4. Hospitals

11. Large Volume Parenteral Market, by Application

  • 11.1. Blood Volume Expansion
  • 11.2. Fluid Replacement
  • 11.3. Medication Delivery
  • 11.4. Nutritional Support

12. Large Volume Parenteral Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Large Volume Parenteral Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Large Volume Parenteral Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Large Volume Parenteral Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Large Volume Parenteral Market

17. China Large Volume Parenteral Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories Inc.
  • 18.6. Albert David Ltd.
  • 18.7. Amanta Healthcare
  • 18.8. B. Braun Melsungen AG
  • 18.9. BAG Healthcare GmbH
  • 18.10. Baxter International Inc.
  • 18.11. Becton Dickinson & Co. (BD)
  • 18.12. Beximco Pharmaceutical Ltd.
  • 18.13. Cipla Limited
  • 18.14. Cook Pharmica LLC
  • 18.15. Fresenius Kabi AG
  • 18.16. Grifols S.A.
  • 18.17. ICU Medical Inc.
  • 18.18. JW Life Science
  • 18.19. Otsuka Pharmaceutical Co. (Otsuka Holdings Co., Ltd.)
  • 18.20. Pfizer Inc. (including Hospira assets)
  • 18.21. Sandoz (a spin-off of Novartis)
  • 18.22. Sichuan Kelun Pharmaceutical Co., Ltd.
  • 18.23. Terumo Corp.
  • 18.24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LARGE VOLUME PARENTERAL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LARGE VOLUME PARENTERAL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY ALBUMIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY DEXTRANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY DEXTRANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY DEXTRANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY GELATINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY GELATINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY GELATINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HYDROXYETHYL STARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HYDROXYETHYL STARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HYDROXYETHYL STARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BALANCED ELECTROLYTE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BALANCED ELECTROLYTE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BALANCED ELECTROLYTE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY DEXTROSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY DEXTROSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY DEXTROSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY NORMAL SALINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY NORMAL SALINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY NORMAL SALINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY RINGER'S LACTATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY RINGER'S LACTATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY RINGER'S LACTATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BAGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BAGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BAGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY PLASTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY PLASTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY PLASTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY GLASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY GLASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY GLASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BLOOD VOLUME EXPANSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BLOOD VOLUME EXPANSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY BLOOD VOLUME EXPANSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY FLUID REPLACEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY FLUID REPLACEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY FLUID REPLACEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY MEDICATION DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY MEDICATION DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY MEDICATION DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY NUTRITIONAL SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY NUTRITIONAL SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY NUTRITIONAL SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 168. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 169. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 170. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 171. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. GCC LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 195. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 196. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 197. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 198. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. G7 LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 204. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 205. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 206. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 207. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. NATO LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL LARGE VOLUME PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, BY COLLOIDS, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, BY CRYSTALLOIDS, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, BY BOTTLES, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA LARGE VOLUME PARENTERAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)